July 1, 2026: More NAION Lawsuits Filed
Semaglutide the active ingredient in Wegovy and Ozempic targets the glucagon-like peptide-1 receptor (GLP-1), which slows digestion, helps people feel fuller longer, triggers the release of insulin, suppresses appetite and lowers blood sugar
Its dual receptor activity suggests potential advantages in metabolic regulation, but more extensive clinical data are needed to confirm its safety and effectiveness
GLP-1 receptor agonists work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity
This was not to say that people in larger bodies need to justify their existence to anyone
Cycling questions dont stop at peptides if youre also using NAD, our guide on how often to take NAD covers the same frequency considerations from the other side